Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Engineered T cell therapy for central nervous system injury [CSF RNAseq + VDJ]

ABSTRACT: Engineered T cell therapy for central nervous system injury [CSF RNAseq + VDJ]

PROVIDER: PRJNA1142026 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30042403_1.fastq.gz	Fastqsanger.gz
	SRR30042403_2.fastq.gz	Fastqsanger.gz
	SRR30042404_1.fastq.gz	Fastqsanger.gz
	SRR30042404_2.fastq.gz	Fastqsanger.gz
	SRR30042405_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Engineered T cell therapy for central nervous system injury [CSF RNAseq + VDJ]

Project description:Traumatic injuries to the central nervous system (CNS) affect millions of people worldwide yet lack an effective treatment. These injuries contain infiltrating immune cells that can promote tissue repair and could be exploited for therapeutic benefit. Here, using single-cell RNA-sequencing of T cells infiltrating the injured CNS we demonstrate their clonal expansion and antigen specificity towards CNS derived self-peptides. We confirm the beneficial effect of these injury-associated autoimmune CD4+ T cells in murine models of optic nerve and spinal cord injury. Subsequently, using mRNA-based transient T cell receptor (TCR) reconstitution, we demonstrate a therapeutic T cell strategy to alleviate CNS injury. Treatment of CNS-injured mice with this therapy improved locomotion and alleviated histological signs of damage, through regulation of myeloid cells, without detrimental autoimmune side effects. This strategy provides a means of developing custom-designed T cell therapies for CNS injury, and possibly for other neurodegenerative disorders.

2024-07-31 | GSE273504 | GEO

GM-CSF in the central nervous system

Project description:The functional outcome of GM-CSF in the central nervous system

| PRJEB27657 | ENA

Engineered T cell therapy for central nervous system injury

Project description:Engineered T cell therapy for central nervous system injury

| PRJNA893390 | ENA

Phosphoproteome Analysis of Cerebrospinal Fluid Extracellular Vesicles in Primary Central Nervous System Lymphoma

Project description:Primary central nervous system lymphoma(PCNSL) is a rare extra-nodal non-Hodgkin’s lymphoma and accounts for 3%-4% of central nervous system tumors. Recent studies have highlighted the importance of cerebrospinal fluid derived extracellular vesicles in PCNSL. Extracellular vesicles(EVs) are nanoscale vesicles with bilayer lipid membrane released by almost all cell types. EVs are present in body fluids, including urine, blood and CSF. Cerebrospinal fluid(CSF) is a colorless fluid that surrounds the brain and spinal cord and acts as lymph in the central nervous system. CSF-derived EVs contain proteins from neurons, oligodendrocytes, astrocytes and microglias. Studies of CSF EVs are mainly limited by the amount of EVs isolated from per milliliter of CSF and the volume of CSF acquired from one patient. Here, we provide a label-free quantitative phospho-proteome profiling of EVs separated from PCNSL and non-PCNSL CSF samples by an earlier introduced functional magnetic beads called EVTRAP together with highly sensitive timsTOF Pro.

2023-07-12 | PXD040744 | JPOST Repository

Engineered T cell therapy for central nervous system injury [FACS-Tcells]

Project description:Engineered T cell therapy for central nervous system injury [FACS-Tcells]

| PRJNA893393 | ENA

Engineered T cell therapy for central nervous system injury [CD45+ scRNA-seq]

Project description:Engineered T cell therapy for central nervous system injury [CD45+ scRNA-seq]

| PRJNA893395 | ENA

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Project description:RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for central nervous system cancer or leptomeningeal metastases. PURPOSE: This phase II trial is studying the side effects and how well iodine I 131 monoclonal antibody 3F8 works in treating patients with central nervous system cancer or leptomeningeal cancer.

| 2037925 | ecrin-mdr-crc

Engineered T cell therapy for central nervous system injury [spinal cord TCR scRNA-seq]

Project description:Engineered T cell therapy for central nervous system injury [spinal cord TCR scRNA-seq]

| PRJNA893396 | ENA

Engineered T cell therapy for central nervous system injury [control tissues TCR scRNA-seq]

Project description:Engineered T cell therapy for central nervous system injury [control tissues TCR scRNA-seq]

| PRJNA784580 | ENA

Efavirenz Central Nervous System Side Effects

Project description:Efavirenz Central Nervous System Side Effects

| PRJNA354669 | ENA